Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Accured Expenses (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Change in Accured Expenses for 12 consecutive years, with $21.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 418.34% to $21.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.6 million, a 233.84% increase, with the full-year FY2025 number at $28.6 million, up 233.84% from a year prior.
  • Change in Accured Expenses was $21.2 million for Q4 2025 at Iovance Biotherapeutics, up from $5.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $21.2 million in Q4 2025 to a low of -$23.0 million in Q1 2024.
  • A 3-year average of $4.7 million and a median of $4.8 million in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 154.2% in 2024, then surged 418.34% in 2025.
  • Iovance Biotherapeutics' Change in Accured Expenses stood at $9.4 million in 2023, then tumbled by 56.58% to $4.1 million in 2024, then soared by 418.34% to $21.2 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Change in Accured Expenses are $21.2 million (Q4 2025), $5.5 million (Q3 2025), and -$281000.0 (Q2 2025).